MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine agonists"

  • 2022 International Congress

    Phantom Pregnancy – A Novel Impulse Control Behaviour in Parkinson’s Disease: A Case Report

    H. Martin, L. Teare (Coventry, United Kingdom)

    Objective: A case report of a phantom pregnancy in a patient with Parkinson’s disease (PD) resulting from impulse control behaviour. Background: Impulse Control Disorders (ICDs)…
  • 2022 International Congress

    Dopamine agonist utilization prior to the initiation of device aided therapy: data from 150 patients with advanced Parkinson’s disease treated with Levodopa Carbidopa Intestinal Gel

    J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, S. Bataga, R. Neagoe, J. Szederjesi, B. Grigorescu, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmari (Targu Mures, Romania)

    Objective: Objective: To evaluate the usage of dopamine agonists (DA) as part of the last conventional dopaminergic treatment in a large cohort of consecutive patients…
  • 2022 International Congress

    Aromatic L-amino acid decarboxylase deficiency: A rare disease case report and literature review

    P. Bacus, R. Sauer, T. Kini, Z. Guduru, K. Jones (Lexington, USA)

    Objective: We review the presentation of a 3-month-old patient who came to our institution with symptoms of dystonia, oculogyric crises, hypotonia, developmental delay, and dysphagia,…
  • 2022 International Congress

    Experience with apomorphine infusion cartridge in France – evaluation of patient and healthcare team benefits

    M. Vérin, M. Demais (Rennes, France)

    Objective: To evaluate ‘real-world’ benefits for patients with Parkinson’s disease (PD) and impact on healthcare team practice of the introduction of apomorphine infusion (APO) cartridge…
  • 2022 International Congress

    USE OF NIGHT TIME CONTINUOUS SUBCUTANEOUS INFUSION OF APOMORPHINE (NCSAI) IN ADVANCED PARKINSON’S DISEASE: A SERIES OF 37 CASES.

    AK. Vargas Mendoza, B. López López, M. Díaz Castela, J. Molina Gil, P. Zunzunegui Arroyo, A. Criado Antón, ME. Suárez Sanmartín, C. García Fernández (Oviedo, Spain)

    Objective: The aim of this study is to evaluate the feasibility, efficacy and safety of NCSAI administration in patients with Advanced Parkinson disease (APD). Background:…
  • 2022 International Congress

    Case report: Parkinsonim with dyskinesia secondary to amyloid angiopathy

    K. Khelfaoui Tredano, G. Berrada, Y. Hsaini, A. Benomar, H. Tibar (Rabat, Morocco)

    Objective: To report a case of parkinsonism secondary to amyloid angiopathy and discuss the pathophysiology and treatment of this entity. Background: Cerebral amyloid angiopathy is…
  • 2022 International Congress

    Availability and accessibility of medicines for patients with Parkinson’s disease in Kyrgyzstan

    C. Shambetova (Bishkek, Kyrgyzstan)

    Objective: The aim of the study was to assess the availability and accessibility of medicines for patients with Parkinson’s disease (PD) in Kyrgyzstan. Background: After…
  • MDS Virtual Congress 2021

    Brain SPECT in Patients with Akinetic-Rigid Syndrome Secondary to Radiotherapy

    C. Soldevila-Lozano, J. Mora-Salvadó, MT. Bajén-Lázaro, L. Rodríguez-Bel, L. Fernández-Romero, M. Cortés-Romera (Barcelona, Spain)

    Objective: The aim of this study is to evaluate the results of brain single photon emission computed tomography (SPECT) with 123-iodine ioflupane in patients with brain…
  • MDS Virtual Congress 2021

    Direct Costs of patients with Parkinson’s Disease in a region of the Brazilian Amazon

    R. Feio, T. França, A. Passos, A. Silva, A. Escudeiro, B. Koshimoto, D. Moura, B. Lobato (Belém, Brazil)

    Objective: To evaluate the perception of the annual direct costs (medications, medical appointments, rehabilitation, transportation) associated with the treatment for patients with PD in the…
  • MDS Virtual Congress 2021

    Limitations of conventional dopaminergic medication in advanced Parkinson’s disease: results from 127 patients treated with Levodopa Carbidopa Intestinal Gel

    J. Szász, V. Constantin, K. Orban-Kiss, L. Bancu, D. Georgescu, J. Szederjesi, M. Ciorba, A. Racz, I. Mihaly, K. Kelemen, S. Szatmari (Targu Mures, Romania)

    Objective: To evaluate the characteristics of the last conventional dopaminergic treatments in a large cohort of patients with advanced Parkinson’s Disease (APD) treated with Levodopa…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #29077 (not found)
  • #29056 (not found)
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28189 (not found)
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley